Understanding persistent bacterial lung infections: Clinical implications informed by the biology of the microbiota and biofilms

Clinical Pulmonary Medicine

Volumn 23, Issue 2, 2016, Pages 57-66

  Pragman, Alexa A ^a   Berger, John P ^a   Williams, Bryan J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis; Microbiota; Sputum culture

Indexed keywords

ANTIBIOTIC AGENT;

ARTICLE; BACTERIAL GROWTH; BIOFILM; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; HUMAN; LUNG INFECTION; MICROFLORA; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE;

EID: 84959933501     PISSN: 10680640     EISSN: 15365956     Source Type: Journal    
DOI: 10.1097/CPM.0000000000000108     Document Type: Article

References (85)

1. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax. 2012;67:1006-1013.
2. Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;12:CD010257.
3. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol. 2003;24(suppl):S6-S52.
4. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr. 2001;139:359-365.
5. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s-53s.
6. Flume PA, VanDevanter DR. Clinical applications of pulmonary delivery of antibiotics. Adv Drug Deliv Rev. 2015;85:1-6.
7. Sorde R, Pahissa A, Rello J. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect Drug Resist. 2011;4:31-41.
8. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(pt 1):1418-1422.
9. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV (1) decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164:358-364.
10. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest. 2000;117(suppl):5S-9S.
11. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589-593.
12. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60:925-931.
13. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev. 2001;14:336-363.
14. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465-471.
15. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891-1904.
16. Smith A. Pathogenesis of bacterial bronchitis in cystic fibrosis. Pediatr Infect Dis J. 1997;16:91-95.
17. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48:1041-1049.
18. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165:847-856.
19. Mayer-Hamblett N, Rosenfeld M, Treggiari MM, et al. Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis. Pediatr Pulmonol. 2013;48:943-953.
20. Zemanick ET, Emerson J, Thompson V, et al. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol. 2014;50:42-48.
21. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J. 2005;26:8-14.
22. Finlayson R. The vicissitudes of sputum cytology. Med Hist. 1958;2:24-35.
23. Blevins SM, Bronze MS. Robert Koch and the "golden age" of bacteriology. Int J Infect Dis. 2010;14:e744-e751.
24. Campbell S, Forbes B. The clinical microbiology laboratory in the diagnosis of lower respiratory tract infections. J Med Microbiol. 2011;49:S30-S33.
25. Wong K, Roberts MC, Owens L, et al. Selective media for the quantitation of bacteria in cystic fibrosis sputum. J Med Microbiol. 1984;17:113-119.
26. Brown J. Use of the Cystic Fibrosis Foundation's extensive sputum-culturing protocol for patients without cystic fibrosis: implications for infection control and antimicrobial resistance. Am J Infect Control. 2014;42:546-547.
27. Smith AL, Fiel SB, Mayer-Hamblett N, et al. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest. 2003;123:1495-1502.
28. Foweraker JE, Laughton CR, Brown DF, et al. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. J Antimicrob Chemother. 2005;55:921-927.
29. van Belkum A, Renders NH, Smith S, et al. Comparison of conventional and molecular methods for the detection of bacterial pathogens in sputum samples from cystic fibrosis patients. FEMS Immunol Med Microbiol. 2000;27:51-57.
30. Rogers GB, Hart CA, Mason JR, et al. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16 S ribosomal DNA (rDNA) length heterogeneity PCR and 16 S rDNA terminal restriction fragment length polymorphism profiling. J Clin Microbiol. 2003;41:3548-3558.
31. Zemanick ET, Wagner BD, Robertson CE, et al. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc. 2014;12:221-229.
32. Wu D, Hou C, Li Y, et al. Analysis of the bacterial community in chronic obstructive pulmonary disease sputum samples by denaturing gradient gel electrophoresis and real-time PCR. BMC Pulm Med. 2014;14:179.
33. Feliziani S, Marvig RL, Lujan AM, et al. Coexistence and withinhost evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections. PLoS Genet. 2014;10:e1004651.
34. Penterman J, Nguyen D, Anderson E, et al. Rapid evolution of culture-impaired bacteria during adaptation to biofilm growth. Cell Rep. 2014;6:293-300.
35. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upperairway specimens can misrepresent lung microbiota. Proc Natl Acad Sci U S A. 2012;109:13769-13774.
36. Brown PS, Pope CE, Marsh RL, et al. Directly sampling the lung of a young child with cystic fibrosis reveals diverse microbiota. Ann Am Thorac Soc. 2014;11:1049-1055.
37. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011;6:e16384.
38. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest. 2002;109:317-325.
39. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008;177:995-1001.
40. Borriello G, Werner E, Roe F, et al. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob Agents Chemother. 2004;48:2659-2664.
41. Sibley CD, Grinwis ME, Field TR, et al. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One. 2011;6:e22702.
42. Twomey KB, Alston M, An SQ, et al. Microbiota and metabolite profiling reveal specific alterations in bacterial community structure and environment in the cystic fibrosis airway during exacerbation. PLoS One. 2013;8:e82432.
43. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184:957-963.
44. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One. 2010;5:e8578.
45. van der Gast CJ, Cuthbertson L, Rogers GB, et al. Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc. 2014;11:1039-1048.
46. Madan JC, Koestler DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio. 2012;3:e00251-12.
47. Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med. 2010;2:29ra31.
48. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445-2454.
49. Huang YJ, Sethi S, Murphy T, et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52:2813-2823.
50. Molyneaux PL, Mallia P, Cox MJ, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;188:1224-1231.
51. Conrad D, Haynes M, Salamon P, et al. Cystic fibrosis therapy: a community ecology perspective. Am J Respir Cell Mol Biol. 2013;48:150-156.
52. Harrison F. Microbial ecology of the cystic fibrosis lung. Microbiology. 2007;153(pt 4):917-923.
53. Ives AR, Carpenter SR. Stability and diversity of ecosystems. Science. 2007;317:58-62.
54. Blaser MJ. The microbiome revolution. J Clin Invest. 2014;124:4162-4165.
55. Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2012;109:5809-5814.
56. Zemanick ET, Harris JK, Wagner BD, et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. PLoS One. 2013;8:e62917.
57. Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr Opin Pediatr. 2011;23:319-324.
58. Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7:e47305.
59. Garcia-Nunez M, Millares L, Pomares X, et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52:4217-4223.
60. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1073-1080.
61. Deschaght P, Schelstraete P, Van SL, et al. Is the improvement of CF patients, hospitalized for pulmonary exacerbation, correlated to a decrease in bacterial load? PLoS One. 2013;8:e79010.
62. Daniels TW, Rogers GB, Stressmann FA, et al. Impact of antibiotic treatment for pulmonary exacerbations on bacterial diversity in cystic fibrosis. J Cyst Fibros. 2013;12:22-28.
63. Price KE, Hampton TH, Gifford AH, et al. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome. 2013;1:27.
64. Stressmann FA, Rogers GB, van der Gast CJ, et al. Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax. 2012;67:867-873.
65. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384:691-702.
66. Sze MA, Hogg JC, Sin DD. Bacterial microbiome of lungs in COPD. Int J Chron Obstruct Pulmon Dis. 2014;9:229-238.
67. Barker BL, Haldar K, Patel H, et al. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest. 2015;147:46-55.
68. Millares L, Ferrari R, Gallego M, et al. Bronchial microbiome of severe COPD patients colonised by Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2014;33:1101-1111.
69. Purcell P, Jary H, Perry A, et al. Polymicrobial airway bacterial communities in adult bronchiectasis patients. BMC Microbiol. 2014;14:130.
70. Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax. 2013;68:731-737.
71. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc. 2014;11:496-503.
72. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-1259.
73. Rogers GB, Bruce KD, Martin ML, et al. The effect of long-term macrolide treatment on respiratory microbiota composition in noncystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014;2:988-996.
74. Harrison J, Turner R, Marques L, et al. Biofilms. American Scientist. 2005;93:508-515.
75. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95-108.
76. Hoiby N, Krogh JH, Moser C, et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect. 2001;3:23-35.
77. Sauer K, Camper AK, Ehrlich GD, et al. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol. 2002;184:1140-1154.
78. Davies JC, Bilton D. Bugs, biofilms, and resistance in cystic fibrosis. Respir Care. 2009;54:628-640.
79. Palmer KL, Mashburn LM, Singh PK, et al. Cystic fibrosis sputum supports growth and cues key aspects of Pseudomonas aeruginosa physiology. J Bacteriol. 2005;187:5267-5277.
80. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318-1322.
81. Hoiby N, Bjarnsholt T, Moser C, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015;21(Suppl 1):S1-S25.
82. Bjarnsholt T, Jensen PO, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44:547-558.
83. Tetz GV, Artemenko NK, Tetz VV. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother. 2009;53:1204-1209.
84. Wolcott R, Costerton JW, Raoult D, et al. The polymicrobial nature of biofilm infection. Clin Microbiol Infect. 2013;19:107-112.
85. Yang DH, Zhang YY, PC DU, et al. Rapid identification of bacterial species associated with bronchiectasis via metagenomic approach. Biomed Environ Sci. 2014;27:898-901.